Dutch authorities hand over final building to EMA in Amsterdam

15 November 2019 - Today, the Dutch authorities have handed over to EMA its newly built tailor-made premises, located in ...

Read more →

DIY drugs: should hospitals make their own medicine?

15 October 2019 - If pharmaceutical companies rapidly inflate the price of their products, is there an alternative? One Dutch chemist ...

Read more →

Dutch experience demonstrates effective benchmarking of biosimilar use in health systems

31 August 2019 - As medicines become more numerous and often more expensive, health care professionals seek new ways to understand ...

Read more →

Dutch health minister threatens to name and shame pharma over prices

28 August 2019 - In an unusual move, the Netherlands health minister wrote an open letter to the pharmaceutical industry ...

Read more →

Dutch minister warns big pharma to come clean on drugs prices

27 August 2019 - Health minister Bruno Bruins has warned the pharmaceuticals industry that he considers the way drugs firms ...

Read more →

Implementation of “coverage with evidence development” drug approval strategies found lacking

15 July 2019 - Lessons from early deployments in The Netherlands. ...

Read more →

Will drugs companies follow EU agency from London to Amsterdam?

16 May 2019 - Amid the bustling skyscrapers of London’s Canary Wharf, one building stands silent and shuttered — a ...

Read more →

Taxpayers are funding expensive drug development, report says

10 May 2019 - The Dutch government invests tens of millions of euros every year in small biotech companies which ...

Read more →

Beneluxa: what are the prospects for collective bargaining on pharmaceutical prices given diverse health technology assessment processes?

23 April 2019 - The Beneluxa collaboration is an initiative aimed at securing sustainable access to new medicines.  ...

Read more →

Conditional financing of drugs in the Netherlands: past, present, and future—results from stakeholder interviews

8 April 2019 - It is long known that managed entry agreements may offer decision makers valuable policy options to ...

Read more →

AbbVie's massive Humira discounts are stifling Netherlands biosimilars

2 April 2019 - Could a drug's price ever be too low? That’s what some market-watchers are asking in the ...

Read more →

EMA now operating from Amsterdam

11 March 2019 - As of today, EMA is operating from Amsterdam.  ...

Read more →

Dutch join backlash at expensive drugs by making their own

8 March 2019 - In a radiation-proof room at the Erasmus Medical Center in Rotterdam, Emar Thomasa sits behind shielded glass ...

Read more →

Determining the comparative value of pharmaceutical risk-sharing policies in non–small cell lung cancer using real-world data

2 March 2019 - Risk-sharing arrangements can be used to mitigate uncertainty about the value of a drug by sharing the ...

Read more →

Pharma lashes out at the Netherlands over drug pricing policies

6 November 2019 - As the Dutch government gets more aggressive about controlling the cost of medicines, the pharmaceutical industry ...

Read more →